Tactile Systems Technology(NASDAQ) TCMD

Tactile helps people manage long-term swelling and breathing issues at home. Its devices make it easier for patients to treat themselves without visiting a clinic. These tools help survivors of cancer and people with chronic lung diseases.

Tools for Swelling and Breathing

• Lymphedema Products: Advanced and basic compression pumps like Flexitouch Plus and Nimbl that reduce swelling; accounts for 83% of revenue.
• Airway Clearance: Portable, wearable vests called AffloVest that help clear lungs for patients with respiratory issues; accounts for 17% of revenue.

Growing the Digital Toolkit

• Acquired LymphaTech, Inc. in February 2026 to add 3D digital measurement and monitoring tools for patients.
• Purchased the AffloVest product line in September 2021 to enter the respiratory therapy market.
• Launched Nimbl in late 2024 and early 2025 as a next-generation platform for treating limb swelling.
• Introduced the Kylee mobile app in July 2022 to help patients track symptoms and treatments on their phones.

Direct Support for Every Patient

The company uses a direct-to-patient model to manage insurance claims and provide training in the home. It maintains an internal clinical team of therapists and doctors to support product development and patient education.

The Latest Financial Results

• Total revenue rose to $75.3 million in Q1 2026, up 22.8% from $61.3 million in Q1 2025.
• Net loss narrowed to $1.8 million in Q1 2026, an improvement from the $3 million loss in Q1 2025.
• Gross profit reached $51.7 million in Q1 2026, up 14% from $45.3 million in the previous year.
• Cash on hand stood at $75 million as of March 31, 2026, following the purchase of LymphaTech.

The Company Today

Tactile has transitioned from a single-product company into a multi-category home health provider. Its focus on digital monitoring and portable therapy supports its growth as a specialist in chronic disease management.